Regulation - Allergan

Filter

Current filters:

Allergan

Popular Filters

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

UK’s MHRA approves Botox for treatment of ankle disability in stroke survivors

04-02-2014

Allergan says that Botox has been approved by the UK’s Medicines and Healthcare Products Regulatory…

AllerganBotoxPharmaceuticalRegulationUK

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues

17-04-2013

US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Watson gets FDA approval for generic Sanctura XR and Avapro

14-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

Botox shows efficacy in idiopathic overactive bladder, says Allergan

29-03-2012

USA-based Allergan (NYSE: AGN) announced that two Phase III clinical trials of Botox (onabotulinumtoxinA),…

AllerganBotoxGenito-urinaryPharmaceuticalRegulationResearch

FDA delay for MAP Pharma migraine drug candidate

28-03-2012

Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday,…

AllerganLevadexMAP PharmaceuticalsMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Back to top